1. Record Nr. UNINA9910484921203321

Titolo	Large and medium size vessel and single organ vasculitis / / edited by Carlo Salvarani, Luigi Boiardi, Francesco Muratore
Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2021] ©2021
ISBN	3-030-67175-5
Descrizione fisica	1 online resource (274 pages)
Collana	Rare Diseases of the Immune System
Disciplina	616.13
Soggetti	Vasculitis Llibres electrònics
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Intro -- Preface -- Contents -- Part I: Giant Cell Arteritis -- 1: Classification Criteria -- References -- 2: Epidemiology and Genetics -- 2.1 Epidemiology -- 2.2 Genetics -- References -- 3: Pathogenesis -- 3.1 Introduction -- 3.2 Model of GCA Pathogenesis -- 3.3 Role of Infectious Agents -- 3.4 Genetics -- 3.5 Immune Effectors of Inflammation in Arteries -- 3.6 Arterial Remodeling -- 3.7 Epigenetics -- 3.8 MicroRNA -- 3.9 Deregulation of the Immune System in Peripheral Blood -- 3.10 Pathways Proven to be Involved in GCA Pathogenesis -- References -- 4: Clinical Manifestations, Differential Diagnosis, and Laboratory Markers -- 4.1 Clinical Manifestations of Giant Cell Arteritis -- 4.2 Differential Diagnosis of Giant Cell Arteritis -- 4.3 Laboratory Markers -- References -- 5: Histopathology and Imaging -- 5.1 Imaging -- 5.2 Temporal Artery Imaging -- 5.3 Large-Vessel Imaging -- References -- 6: Prognosis and Disease Activity -- 6.1 Risk for Complications and Comorbidities During Disease Course -- 6.2 Risk Factors and Biomarkers for Disease Activity in Giant Cell Arteritis -- 6.3 Additional Biomarkers for Assessment of Prognosis-Relevant Comorbidities -- References -- 7: Treatment and Management -- 7.1 General Aspects -- 7.2 Glucocorticoids as First-Line Treatment -- 7.3 Glucocorticoid(GC)-Sparing Agents -- 7.4 Treatment of Comorbidities/Adjuvant Therapies -- References -- Part II: Takayasu Arteritis -- 8: Classification Criteria,

Epidemiology and Genetics -- and Pathogenesis -- 8.1 Classification Criteria -- 8.2 Epidemiology and Genetics -- 8.2.1 Incidence and Prevalence -- 8.2.2 Sex -- 8.2.3 Age at Diagnosis -- 8.2.4 Major Histocompatibility Complex -- 8.2.5 Non-MHC -- 8.3 Pathogenesis -- References -- 9: Clinical Manifestations, Differential Diagnosis, and Laboratory Markers -- 9.1 Clinical Manifestations.
9.2 Physical Examination -- 9.3 Laboratory: Role of Acute-Phase Response -- 9.4 Differential Diagnosis -- 9.5 Large-Vessel Vasculitis Mimickers in the Differential Diagnosis of TAK -- References -- 10: Imaging -- 10.1 CTA -- 10.2 MRA -- 10.3 FDG-PET -- 10.4 Ultrasonography -- 10.5 Conclusion -- References -- 11: Prognosis and Disease Activity -- 11.1 Disease Activity Assessment -- 11.1.1 Physical Examination in Clinical Activity Assessment -- 11.1.2 Laboratory in Disease Activity Assessment -- 11.1.3 Imaging in Disease Activity Assessment -- 11.1.4 Outcome Measures in Disease Activity Assessment -- 11.2 Prognosis -- 11.2.1 Disease Course -- 11.2.2 Damage Assessment in TAK -- 11.2.3 Mortality -- 11.3 Conclusion -- References -- 12: Treatment -- 12.1 Non-biologic Disease-Modifying Agents -- 12.1.1 Methotrexate -- 12.1.2 Azathioprine -- 12.1.3 Leflunomide -- 12.1.4 Mycophenolate Mofetil -- 12.1.5 Cyclophosphamide -- 12.1.6 Other Non-biologic Disease-Modifying Agents -- 12.2 Biologic Disease-Modifying Agents -- 12.2.1 Tumor Necrosis Factor Inhibitors -- 12.2.2 Tociluzumab -- 12.2.3 Rituximab -- 12.2.4 Other Biologic Disease-Modifying Agents -- 12.3 Vascular Interventions and Surgical Therapy -- 12.4 Conclusion -- References -- Part III: Polyarteritis Nodosa -- 13: Cutaneous Polyarteritis Nodosa -- 13.1 Introduction -- 13.2 Epidemiology, Genetics, Pathogenesis -- 13.3 Clinical Manifestations and Laboratory Markers -- 13.3.1 Clinical Manifestations -- 13.3.2 Laboratory Markers -- 13.4 Histopathology -- 13.5 Diagnosis and Differential Diagnosis -- 13.6 Treatment -- 13.7 Prognosis and Disease Activity -- References -- 14: Systemic Polyarteritis Nodosa -- 14.1 Introduction -- 14.2 Epidemiology -- 14.3 Etiopathogenesis -- 14.4 Clinical Manifestations and Laboratory Markers -- 14.4.1 Clinical Manifestations.
14.4.2 Laboratory Markers -- 14.5 Histopathology -- 14.6 Diagnosis and Differential Diagnosis -- 14.7 Prognosis -- 14.8 Treatment -- References -- Part IV: Single Organ Vasculitis -- 15: Adult Primary Central Nervous System Vasculitis -- 15.1 Introduction -- 15.2 Diagnosis and Diagnostic Criteria -- 15.3 Histopathology -- 15.4 Clinical Manifestations and Laboratory Findings -- 15.5 PCNSV Subsets -- 15.6 Differential Diagnosis -- 15.7 Treatment -- 15.7.1 Mayo Clinic Cohort of Patients with Adult PCNSV -- 15.7.2 French Cohort of Patients with Primary Central Nervous System Vasculitis -- 15.7.3 Monitoring Disease Course -- References -- 16: Isolated Aortitis and Periaortitis -- 16.1 Introduction -- 16.2 Clinical Features and Diagnosis -- 16.2.1 Isolated Aortitis -- 16.2.2 Periaortitis -- 16.2.3 IgG4-Related Aortitis and Periaortitis -- 16.3 Treatment -- 16.4 Conclusions -- References -- 17: Isolated Gastrointestinal Vasculitis -- 17.1 Introduction -- 17.2 Epidemiology -- 17.3 Clinical Manifestations -- 17.4 Diagnosis -- 17.5 Differential Diagnosis -- 17.6 Management -- 17.7 Prognosis -- References -- 18: Cutaneous Vasculitis -- 18.1 Introduction -- 18.2 Nomenclature and Classification of Cutaneous Vasculitis -- 18.3 Clinical Spectrum of Cutaneous Vasculitis -- 18.4 Cutaneous Vasculitic Manifestations in Systemic Vasculitides with Predominant Organ Involvement Different from the Skin -- 18.4.1 Polyarteritis Nodosa -- 18.4.2 Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis --